Beijing Prohibits Drug Price Mark-up Beyond 15 Percent
This article was originally published in PharmAsia News
Beijing's Development and Reform Commission recently announced that all municipal county-level and higher medical institutions will be strictly prohibited from increasing drug prices beyond 15 percent of actual procurement prices
You may also be interested in...
The EU is pulling out all the stops to have the one-year delay to the MDR adopted before it is too late, and a crucial vote will take place on 16 April.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
Virtual notified body audits of medtech manufacturers are already taking place through necessity. Now there is guidance concerning if, when, where and how these audits should be carried out.